Opdivo (nivolumab)

Extended follow-up results of the #CheckMate274 trial. @MattGalsky @TischCancer & @UroCancerMD @VUMCurology discuss the long-term results showing continued DFS benefits of adjuvant nivolumab vs PBO in high-risk muscle-invasive urothelial cancer patients > https://t.co/367pewfVsM (@urotoday)

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial #ACScancerchat (@drfrankiejs)

Professor Scolyer, what is the plan of attack? Are you going to hit it with Ipi+nivo? 10 years ago in June of 2013 I was diagnosed stage 4 melanoma brain and lung mets. Part of checkmate 067, Nivo arm of trial after SRS cyberknife for 3 small brain mets. Best Wishes!!! (@EdWilli63968626)

Targeting the microbiome with CBM588 in combination with ipi-nivo or cabo-nivo looks one of the most promising novel approaches in RCC ⁦@DrRanaMcKay⁩ #KCRS23 (@tompowles1)

Important talk by @tompowles1 discussing emerging biomarkers for nivolumab + ipilimumab among patients with #mRCC in light of novel findings from the PRISM trial #KCRS23 #Biomarkers #KidneyCancer (@kidneycan)

S7: Oral Abstract 🩸 Circulating KIM-1 is a Minimally Invasive Biomarker Correlated with Response to Nivo in RCC Retrospective analysis of pt treated with Nivo on CM009 ⬇️Decrease in KIM1 a/w PFS HR 0.22! @VincentWenxinXu @DanaFarber_GU @kidneycan #KCRS23 (@MikeSerzanMD)

Dr. @EJonasch presented STARLITE 1 Phase 1/2 trial evaluating 177Lu-Girentuximab plus Cabozantinib and Nivolumab in patients with clear cell RCC. #KCRS23 (@FabioSchutz78)

@EJonasch on the STARLITE 1: a phase 1/2 study of combination 177Lu Girentuximab plus Cabo and Nivo in ccRCC @kidneycan #KCRS23 (@MosheOrnsteinMD)

S3: Trials In Progress ⭐️ STARLITE 1 Phase 1/2 Study of Combo 177Lu Girentuximab + Cabo + Nivo in Treatment Naive ccRCC @EJonasch @MDAndersonNews @DrEHasanov @kidneycan #KCRS23 (@MikeSerzanMD)

Amazing data! Along with recent cabo/nivo data in non-ccRCC, these data further support IO/TKI as a SOC Tx option for many pts with nccRCC. Gr8 to have multiple prospective IO/TKI datasets. Congrats @AlbigesL and team and kudos to pharma for funding trials in rare disease subsets (@MosheOrnsteinMD)

Upfront Nivolumab/Chemotherapy Prolongs Survival in Unresectable/Metastatic Urothelial Carcinoma https://t.co/bByImciU8C via @targetedonc @MattGalsky @IcahnMountSinai (@TischCancer)

Nivo with cisplatin based chemo improves OS and PFS in met #bladdercancer — great to see positive trial. Looking forward to seeing the curves at #ESMO23 @myESMO! (@TiansterZhang)

Cisplatin based chemotherapy + Nivolumab improves outcomes in metastatic urothelial cancer. https://t.co/LiF9jQmcKj @UroDocAsh @Uromigos @neerajaiims @DrYukselUrun @OncoAlert @TischCancer @montypal (@MattGalsky)

2-year follow-up data from the RELATIVITY-047 trial showed a continued benefit for previously untreated, unresectable melanoma treated w/ nivo + relatlimab vs nivolumab monotherapy, supporting the use of the combination. @HTawbi_MD @MDAndersonNews #melsm https://t.co/ur9TKainmM (@OncLive)

Great presentation by our colleague and friend @boutrosand on 2nd day of this Young @AIOMtweet 2023 on melanoma. 🔎 focus on: 1. mRNA vaccine + Pembro promising adjuvant therapy 2. IPI+NIVO 1st standard line even in BRAFm 3. Tebentafusp standard tp for uveal metastatic melanoma (@Lucarecco)

Phase ✌🏽 NADIM II: Perioperative Nivolumab & Chemotherapy in Stage IIIA/IIIB Non-Small Cell Lung Cancer ▪️pCR 37% (v 7% chemo alone) ▪️2yr PFS rate 67% (v 41%) ▪️2yr OS rate 85% (v 64%) 👉🏼 https://t.co/lbBImZJlAk @ASCOPost @NEJM @LungCancerRx #lcsm (@esinghimd)

Based on the latest updates from CLEAR and KN-426 ASCO-2023, it appears that IO-TKI may have lower durability compared to IO-IO. Should we consider IPI-NIVO as the first-line standard of care for patients with sarcomatoid features, irrespective of their IMDC risk! (@DrYukselUrun)

Updates on NCI9673 nivo +/- ipi in ref advanced #analcancer by @VanMorrisMD, largest randomized IT trial in this space, discussion by Dr. Juan Manuel O'Connor ->no significant PFS difference, a subgroup experienced long-term disease control, needs correlative studies @WCGIC (@ThejusJay)

Nivo + relatlimab showed a continued benefit vs nivo monotherapy for previously untreated, unresectable melanoma, according to 2-year follow-up data from the RELATIVITY-047 trial, supporting the use of the combination. @HTawbi_MD @MDAndersonNews #melsm https://t.co/MDyXyjRuby (@OncLive)

Phs II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal #WCGIC2023 👉Trend for higher efficacy with dual ICI, but also more toxicity 👉We need predictive biomarkers @myESMO @OncoAlert @WCGIC (@ArndtVogel)

Perioperative Nivolumab and Chemotherapy in stage III Non-Small-Cell Lung Cancer - @RManochakian #cancer #lungcancer #drugs #chemotherapy #neoadjuvant #nivolumab #oncology #oncodaily https://t.co/VXSPb5htgV (@oncodaily)

Excellent discussion @Juanmaoconnor!! "Genomic landscape of appendiceal adenocarcinoma" @michaelwhitewx and "Nivo with or without ipilimumab in m squamous cell carcinoma of the anal canal" @VanMorrisMD #WCGIC2023 (@CataniGreta)

Outstanding achievement for #LungCancer treatment #NADIM2. Stage IIIA-IIIB resectable NSCLC: Neoadj nivo/chemo + adj nivo vs Neoadj chemo: ➡️ pCR 37% ➡️ 2-yr OS 85% Congratulations to @MARIANOPROVENCI and the entire team. #MadeInSpain 🇪🇸🇪🇸🇪🇸 (@AndresObesoMD)

Big step in lung cancer treatment. Stage IIIA-IIIB resectable NSCLC: Neoadj nivo/chemo + adj nivo vs Neoadj chemo: ➡️ pCR 37% ➡️ 2-yr OS 85% @MARIANOPROVENCI (@CompostelaT)

.@VanMorrisMD @MDAndersonNews presenting the results from the NCI9673 part B trial of nivo +/- ipi in refractory advanced #analcancer - unfortunately no statistical difference in ORR, PFS, or OS, correlative studies planned #WCGIC2023 @WCGIC (@benweinbergmd)

Thank you for posting this information and please continue to do so. I am currently going to have nivolumab, which tests show I´m sensitive to. I If you have more info on them I appreciate it. Stage 4 colon cancer survivor. 🙏 (@JayneDutra)

.@DrChoueiri and Rohit Gosain, MD, reviewed results from the phase 3 CheckMate 9ER trial which asseed nivolumab plus cabozantinib vs sunitinib in patients with renal cell carcinoma. #rccsm https://t.co/Sahrg8aNOy (@CancerNetwrk)

Ipilimumab and nivolumab treatment in patients with stage III #UrothelialCancer. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work by van Dorp et al. in @NatureMedicine. #ReadNow > https://t.co/UIVqfb7oNw (@urotoday)

Deciphering immunotherapy responses in advanced #RCC: a deep dive into the HCRN study. Join @Nourhanelahmar @BrighamWomens and @PBarataMD @caseccc in discussing a subgroup analysis of the HCRN GU16-260 platform study, of nivo and ipi as salvage therapy > https://t.co/ky92Q1YAsu (@urotoday)

Adj nivolumab vs plc in resected esophageal or GEJ cancer following neoadjuvant CRT: biomarker analyses from CheckMate 577 by R. Kelly at #WCGIC2023 👉Benefit in multiple (inflammatory) subgroups 👉Increase in PDL1 expression in 51% post-CRT @myESMO @WCGIC (@ArndtVogel)

VESTIGE: Adjuvant immunotherapy in pts with resected GEA following preoperative chemotherapy with high risk for recurrence presented by @LizzySmyth1 at #WCGIC2023 🔎EORTC phs II study unfortunately⛔️ 👉Adj. Nivo/IPI did not improve DFS & OS compared to CTx @myESMO @WCGIC… https://t.co/lSFVIYRKdE (@ArndtVogel)

Adj nivolumab vs plc in resected esophageal or GEJ cancer following neoadjuvant CRT: biomarker analyses from CheckMate 577 by R. Kelly at #WCGIC2023 👉Benefit in multiple (inflammatory) subgroups 👉Increased PDL-1 expression in 51% post-CRT @myESMO @WCGIC (@ArndtVogel)

Interesting data from the CM577, PD-L1 CPS increase post-CRT, and the magnitude of benefit with adjuvant Nivolumab appeared to be greater in patients with increase in PD-L1 CPS post-CRT #WCGIC2023 (@MoniquMeneses)

Adjuvant ipi/nivo in LA gastric cancer ypN1-N3 R0/R1 did not improved DFS… interesting, patients on postoperative FLOT arm continue to receive benefit of chemotherapy, VESTIGE results presented at #WCGIC2023 #GItumors #GIcancers (@MoniquMeneses)

🤜Towards Lung Cancer Cure. @gecp_org @MARIANOPROVENCI Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM https://t.co/hJxBkcRQKx (@LiquidBiopsyLab)

Relapsed Hodgkins If patient has progressed on single agent Nivo please don’t switch them to single agent Pembro Use something else @nihardesai7 @PallawiTorkaMD (@BijoyTelivala)

The Phase 1B #NABUCCO trial: the use of either high or low-dose preoperative ipilimumab + nivolumab in patients with stage III #UrothelialCancer. Michiel Van Der Heijden, PhD @NKI_nl joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/jkHcJteQM4 (@urotoday)

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma. @bvantine1 #ASCO23 #scmsm https://t.co/L2XDmf5V2X (@OncLive)

Nivolumab + ipilimumab & chemotherapy continued to show durable benefit at 4 years compared w/ chemotherapy alone as first-line therapy in patients w/ advanced NSCLC, particularly in the PD-L1– and squamous populations. @DCarboneMD @OSUCCC_James #lcsm https://t.co/ShCsWZk0UO (@OncLive)

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma. @bvantine1 #ASCO23 #scmsm https://t.co/y2zTzmIEVd (@OncLive)

✅ Nivolumab and Chemoradiation HNSCC: DEPEND Trial 📹 video https://t.co/9h1zNBtsGS #HNSCC #DependTrial #CancerResearch #ASCO23 @AriRosenbergMD @UChicago (@oncologytube)

PD-1 refractory or stable Hodgkin disease patients had response to nivolumab combination with ruxolitinib (@SabarishMD)